Karyopharm Therapeutics presents clinical data on Selinexor (KPT-330) in colorectal cancer from ongoing Phase 1 study and preclinical data on novel PAK4 inhibitors at American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium; Data demonstrate preliminary evidence of anti-tumor activity of oral selinexor in colorectal cancer patients (KPTI) :
Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients
Potential Anti-Proliferative Activity of Novel PAK4 Inhibitor Seen in Preclinical Pancreatic Cancer Model
Co announced data from two poster presentations at the American Society of Clinical Oncology (TATD) 2014 Gastrointestinal (:GI) Cancers Symposium that took place January 16-18 in San Francisco, California.
The data presented included an update (as of December 16, 2013) from the ongoing Phase 1 study of oral Selinexor in solid tumors that show preliminary evidence of antitumor activity in metastatic colorectal cancer (:CRC) patients. Additionally, data were presented on novel, oral p21-activated kinase 4 (PAK4) inhibitors that show anti-proliferative activity and tolerability in a preclinical pancreatic cancer model.
"We are very pleased with these preliminary results showing that single agent oral Selinexor has the potential to provide disease control in a subset of patients with heavily pretreated CRC. We are currently continuing our Phase 1 dose expansion cohorts and expect to report more data at the annual ASCO conference in June," stated Sharon Shacham, Ph.D., founder, Chief Scientific Officer and President of Karyopharm. "In addition, the preliminary preclinical data on our compounds that selectively inhibit PAK4 support our continued development of these potential therapies towards first-in-human studies."
8:35 am Hemispherx Biopharma analysis of new data on protection from pulmonary damage associated with infection by highly pathogenic influenza virus (HEB) :
Co announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21, 2014 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1) by Low Dose Natural Human IFN-a Administered to the Buccal Mucosa." This presentation is a collaborative project conducted at Viroclinics, Rotterdam, an internationally recognized research entity for the study of both seasonal and pandemic influenza viruses. The biohazard facilities are directed by Prof. Albert D.M.E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza.
Thus, both H5N1 influenza virus (the subject of collaboration with the Osterhaus group) and H7N9 influenza virus (the subject of ongoing collaboration with Prof. J. Richt's group at the Center of Excellence for Emerging and Zoonotic Animal Diseases (:CEEZAD), Kansas State University (please see Expert Review of Anti-infective Therapy (online edition, pages 1-5, 2014) are susceptible to Alferon N treatment in various model systems.
Both H5N1 influenza virus and H7N9 influenza virus have recently lead to an increased incidence of clinical disease in various parts of the world.
The new study shows the importance of the interferon induced pathways in controlling influenza viral infection. No deaths were observed in individuals with the wildtype genotype, compared to a 33% mortality rate in patients with the dysfunctional interferon pathway genotype.
